Key TakeawaysOSCR stock surged approximately 11% on Wednesday following CEO Mark Bertolini’s acquisition of 1 million shares at $11.92 apiece.The $11.92M investment came through a private placement structure rather than open-market trading — new shares were created and sold directly to the executive.Bertolini’s holdings now total 10.2M shares, giving him a 10.87% ownership position in Oscar Health.The stock had previously gained roughly 7% on Tuesday when federal officials announced a 2.5% increase in Medicare Advantage payment rates for 2027.Despite reporting $443.2M in net losses for 2025, Oscar projects explosive 60% revenue expansion in 2026, forecasting $18.7B–$19B in total revenue.Oscar Health (OSCR) is currently changing hands at $14.43, representing a gain of $2.21 (+15.29%) from the previous session as of the opening bell.Oscar Health, Inc., OSCROscar Health’s chief executive Mark Bertolini captured investor attention this week with a substantial personal investment — acquiring 1 million shares of OSCR at $11.92 per share, totaling $11.92M. The health insurance company’s stock responded with an approximate 11% climb on Wednesday morning.Regulatory disclosures filed after Tuesday’s closing bell revealed the transaction, which Bertolini executed on Monday, April 6. The former Aetna CEO’s move represents a significant vote of confidence in the insurer’s strategic direction.However, this wasn’t a conventional market transaction. SEC Form 4 documentation clarifies the deal as a private placement — Oscar created and issued 1 million fresh shares directly to Bertolini at the $11.92 closing price, identical to the valuation used that day for tax withholding on his vested performance-based equity awards.The arrangement infused Oscar with $11.92M in new capital while expanding Bertolini’s ownership to 10.87% of the company — a total of 10,196,876 shares. The dilutive impact on existing shareholders remained relatively modest.Financial Performance OverviewOscar’s 2025 results showcase a rapidly expanding enterprise still working toward profitability. Annual revenue reached $11.7B, accelerating from $9.18B the previous year. Member enrollment hit an all-time high of 3.4 million individuals. The company recorded $443.2M in net losses, with operating deficits of $396.4M.Looking ahead to 2026, management projects $18.7B–$19B in revenue — representing approximately 60% year-over-year expansion — while targeting a medical-loss ratio between 82.4% and 83.4%. Wall Street analysts forecast earnings per share of $0.77 for 2026, which would signal the company’s shift into positive territory.Those are ambitious objectives. Bertolini’s multimillion-dollar investment suggests he believes the company can deliver.For context, consider the established giants: UnitedHealth Group reported Q4 2025 revenue of $113.2B, reflecting 12.3% growth year-over-year. Centene and Molina Healthcare expanded at more modest rates. Oscar’s growth trajectory significantly outpaces these incumbents, even as the path to sustained profitability remains under construction.Understanding the Transaction StructureIt’s important to distinguish what occurred here from other forms of insider buying. A traditional open-market purchase — where an executive buys shares at prevailing ask prices, accepting market friction and potential immediate unrealized losses — typically sends the strongest confidence signal. That approach communicates: “I believe in this valuation today.”A private placement operates differently. Bertolini didn’t independently decide to enter a market order. He acquired equity at a predetermined fair market value as part of a structured transaction connected to compensation vesting. The company received capital; he increased his shareholding position.That said, Bertolini had alternatives. He could have liquidated vested shares to satisfy tax obligations and pocketed cash instead. He opted to expand his ownership. At today’s trading levels, his Oscar stake is valued at approximately $125M.OSCR shares had already climbed roughly 7% on Tuesday following the federal government’s confirmation of a 2.5% Medicare Advantage reimbursement rate increase for 2027 — exceeding earlier proposals that suggested flat rates.Oscar is scheduled to release Q1 2025 financial results on May 6 before market hours.The post Oscar Health (OSCR) Stock Surges 15% as CEO Invests Nearly $12M in Company Shares appeared first on Blockonomi.